(Q38039263)

27 August 2017

title

Epilepsy meets cancer: when, why, and what to do about it? (English)

1 reference

27 August 2017

1

Michael Weller

1 reference

27 August 2017

3

Wolfgang Wick

1 reference

27 August 2017

2

Roger Stupp

1 reference

27 August 2017

publication date

1 September 2012

1 reference

Lancet Oncology Commission

27 August 2017

published in

1 reference

27 August 2017

volume

13

1 reference

27 August 2017

issue

9

1 reference

27 August 2017

page(s)

e375-82

1 reference

Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Drug interactions between chemotherapeutic regimens and antiepileptics.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Drug-resistant epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Cancer risk in people with epilepsy: the role of antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Cancer risk in people with epilepsy using valproate-sodium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Epilepsy in low‐grade gliomas: The impact on cognitive function and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Efficacy of anti-epileptic drugs in patients with gliomas and seizures.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Convection-enhanced delivery in the treatment of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Prognostic factors and outcome after different types of resection for temporal lobe epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Predictors of seizure freedom after resection of supratentorial low-grade gliomas. A review.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Seizure characteristics and control following resection in 332 patients with low-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Neuron-like physiological properties of cells from human oligodendroglial tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Gene expression profile analysis of epilepsy-associated gangliogliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Anomalous levels of Cl- transporters cause a decrease of GABAergic inhibition in human peritumoral epileptic cortex

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

The role of inflammation in epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Increased indoleamine 2,3-dioxygenase (IDO) activity in idiopathic generalized epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

The activity of antiepileptic drugs as histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Histone deacetylase inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Preoperative valproate administration does not increase blood loss during temporal lobectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Effect of valproic acid on the outcome of glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

1 reference

7 January 2021

Reproductive health effects and teratogenicity of antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Epilepsy in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

Modern management of epilepsy: a practical approach

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970266-8

7 January 2021

10.1016/S1470-2045(12)70266-8

Identifiers

DOI

1 reference

27 August 2017

1 reference